Bundamedik (IDX:BMHS) - Share price, News & Analysis

BMHS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

BMHS Stock Overview

PT Bundamedik Tbk provides health care services.

Rewards

Revenue is forecast to grow 14.5% per year

Earnings grew by 142.5% over the past year

Risk Analysis

No risks detected for BMHS from our risk checks.

Bundamedik Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bundamedik
Historical stock prices
Current Share Price	Rp590.00
52 Week High	Rp1,200.00
52 Week Low	Rp424.00
Beta	0
1 Month Change	-16.31%
3 Month Change	-18.06%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	39.15%

Shareholder Returns

	BMHS	ID Healthcare	ID Market
7D	3.5%	4.2%	3.1%
1Y	n/a	18.6%	18.2%

Return vs Industry: Insufficient data to determine how BMHS performed against the ID Healthcare industry.

Return vs Market: Insufficient data to determine how BMHS performed against the ID Market.

Price Volatility

Is BMHS's price volatile compared to industry and market?
BMHS volatility
BMHS Average Weekly Movement	5.4%
Healthcare Industry Average Movement	5.4%
Market Average Movement	6.2%
10% most volatile stocks in ID Market	12.1%
10% least volatile stocks in ID Market	3.0%

Stable Share Price: BMHS is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: BMHS's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1973	1,117	Mesha Sini	https://www.bmhs.co.id

PT Bundamedik Tbk provides health care services. As of December 31, 2020, the company operated 2 maternal and children’s hospitals, 3 general hospitals, 2 clinics, 10 IVF clinics, and 14 diagnostic laboratories. It also engages in the distribution of pharmaceuticals and medical devices; and hotel, medical tourism, and management consulting businesses.

Bundamedik Fundamentals Summary

How do Bundamedik's earnings and revenue compare to its market cap?
BMHS fundamental statistics
Market Cap	Rp5.08t
Earnings (TTM)	Rp215.30b
Revenue (TTM)	Rp1.71t

23.6x

P/E Ratio

3.0x

P/S Ratio

Is BMHS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMHS income statement (TTM)
Revenue	Rp1.71t
Cost of Revenue	Rp910.98b
Gross Profit	Rp799.78b
Other Expenses	Rp584.48b
Earnings	Rp215.30b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	25.02
Gross Margin	46.75%
Net Profit Margin	12.58%
Debt/Equity Ratio	36.4%

How did BMHS perform over the long term?

See historical performance and comparison

Valuation

Is Bundamedik undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

23.58x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: BMHS (IDR590) is trading above our estimate of fair value (IDR300.79)

Significantly Below Fair Value: BMHS is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: BMHS is poor value based on its PE Ratio (23.6x) compared to the ID Healthcare industry average (19.7x).

PE vs Market: BMHS is poor value based on its PE Ratio (23.6x) compared to the ID market (18.5x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMHS's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BMHS is overvalued based on its PB Ratio (3.3x) compared to the ID Healthcare industry average (1.9x).

Future Growth

How is Bundamedik forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

14.5%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if BMHS's forecast earnings growth is above the savings rate (7%).

Earnings vs Market: Insufficient data to determine if BMHS's earnings are forecast to grow faster than the ID market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BMHS's revenue (14.5% per year) is forecast to grow faster than the ID market (11.3% per year).

High Growth Revenue: BMHS's revenue (14.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BMHS's Return on Equity is forecast to be low in 3 years time (15.6%).

Past Performance

How has Bundamedik performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

142.5%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: BMHS has high quality earnings.

Growing Profit Margin: BMHS's current net profit margins (12.6%) are higher than last year (7.7%).

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BMHS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare BMHS's past year earnings growth to its 5-year average.

Earnings vs Industry: BMHS earnings growth over the past year (142.5%) exceeded the Healthcare industry 121.6%.

Return on Equity

High ROE: BMHS's Return on Equity (18.7%) is considered low.

Financial Health

How is Bundamedik's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: BMHS's short term assets (IDR1,009.6B) exceed its short term liabilities (IDR726.5B).

Long Term Liabilities: BMHS's short term assets (IDR1,009.6B) exceed its long term liabilities (IDR274.4B).

Debt to Equity History and Analysis

Debt Level: BMHS has more cash than its total debt.

Reducing Debt: Insufficient data to determine if BMHS's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BMHS's debt is well covered by operating cash flow (42.4%).

Interest Coverage: BMHS's interest payments on its debt are well covered by EBIT (48.4x coverage).

Balance Sheet

Dividend

What is Bundamedik current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

1.22%

Forecast Dividend Yield

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMHS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMHS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMHS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMHS's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMHS has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Mesha Sini (46 yo)

no data

Tenure

Ir. Mesha Rizal Sini, M. Eng, SH is President Director of PT Bundamedik Tbk and is also a commissioner of PT. Bunda Investama Indonesia. He completed education in mechanical engineering at Trisakti Univers...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: BMHS only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/05/21 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31